The Board of Eliem Therapeutics, Inc. has approved a corporate reorganization plan to conserve financial resources. As part of the reorganization, the Company will reduce its workforce by approximately 55% in the first half of 2023. In connection with this reorganization, Bob Azelby, chief executive officer will be departing the Company and the Board imminently.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.43 USD | +5.36% | -7.93% | +246.30% |
04-11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
04-11 | Top Midday Gainers | MT |
1st Jan change | Capi. | |
---|---|---|
+246.30% | 251M | |
+3.15% | 108B | |
+10.38% | 104B | |
+0.32% | 22.33B | |
-11.70% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.13% | 17.64B | |
+6.41% | 14.05B | |
+37.17% | 12.51B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc